European regulators have approved Novartis’ Kymriah and Gilead’s Yescarta, enabling patients to access CAR-T therapies across the region for the first time. More: EU approves first CAR-T therapies Source: News
read moreUS regulators have rejected Akcea/Ionis’ application to market Waylivra for the ultra-rare rare lipid disorder familial chylomicronemia syndrome (FCS). More: FDA rejects Akcea/Ionis’ rare disease drug Waylivra Source: News
read moreAs President Donald Trump and his administration work to tackle the opioid epidemic, two Democratic senators are looking into whether his personal attorney Rudy Giuliani secured leniency for opioid maker Purdue Pharma through conflicts of interest. More: Senators question whether
read moreThis year’s big questions for the European Society of Cardiology Congress? Whether Pfizer’s tafamidis can sweep aside Alnylam’s only-just-approved rare disease drug Onpattro, Esperion’s cholesterol hopeful bempedoic acid can find a sweet spot and J&J and Bayer’s Xarelto can turn trial
read moreWhat a comedown for Johnson & Johnson’s Xarelto at the European Society of Cardiology annual meeting. Last year, J&J touted data that put the clot-buster on track for a new $1 billion-plus approval. This time, the company was forced to
read moreTwo months ahead of the FDA decision date, the agency approved AbbVie and J&J’s Imbruvica, plus Roche’s Rituxan, to treat adults with a rare blood cancer. The approval will provide patients and doctors with the first chemo-free option to treat
read more© 1994 - 2026 B.M. Pharmaceuticals